Our mission is to enable use of live cells to personalize drug development and treatment selection for patients with solid tumor cancers. We have developed the patented SnapPath Cancer Diagnostics System - the only diagnostics system that can generate purified populations of live solid tumor cells from live, unfixed samples in an automated and standardized manner. SnapPath preserves molecular integrity of these living cells for ex vivo exposure to targeted therapies. This enables generation of PathMap Functional Signaling Profiles, which are highly predictive of individual solid tumor response to targeted therapies and combinations, because they are based on the dynamic signaling information available only from live cells. This functional information is required to understand initial response and the acquired resistance that too often develops in the treatment of cancer.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
SnapPath Cancer Diagnostics System
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):